|
| 37767768 | Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma. | Blood Cancer Discov | 2024 |
| 37934799 | ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma. | Blood Cancer Discov | 2024 |
| 37729611 | Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency. | Blood | 2024 |
| 36861343 | In vivo characterization of the critical interaction between the RNA exosome and the essential RNA helicase Mtr4 in Saccharomyces cerevisiae. | G3 (Bethesda) | 2023 |
| 37526080 | Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. | J Clin Invest | 2023 |
| 37956312 | Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors. | Cancer Res Commun | 2023 |
| 37237081 | Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. | Nat Cancer | 2023 |
| 35927247 | Venetoclax ex vivo functional profiling predicts improved progression-free survival. | Blood Cancer J | 2022 |
| 35511673 | β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. | Haematologica | 2022 |
| 35380688 | PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival. | Mol Cancer Res | 2022 |
| 35565356 | Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients. | Cancers (Basel) | 2022 |
| 35357482 | Agent myeloma has a new weapon from (ch1)Q. | Blood | 2022 |
| 36170375 | Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma. | Sci Adv | 2022 |
| 33275813 | Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. | Am J Hematol | 2021 |
| 33738338 | Oncolytic herpes simplex virus infects myeloma cells <i>in vitro</i> and <i>in vivo</i>. | Mol Ther Oncolytics | 2021 |
| 33737856 | BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma. | Blood Lymphat Cancer | 2021 |
| 33649772 | Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. | Blood | 2021 |
| 33731701 | Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. | Nat Commun | 2021 |
| 33731366 | Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. | Clin Cancer Res | 2021 |
| 33634031 | Game of Bones: How Myeloma Manipulates Its Microenvironment. | Front Oncol | 2021 |
| 34638271 | Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. | Cancers (Basel) | 2021 |
| 34778800 | Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. | Blood Cancer Discov | 2021 |
| 33406420 | Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. | Cell Rep | 2021 |
| 33368455 | Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. | Am J Hematol | 2021 |
| 32286263 | Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. | Blood Cancer J | 2020 |
| 32579940 | CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell Survival. | Cell Rep | 2020 |
| 32739887 | BCL2 dependency in diffuse large B-cell lymphoma: it's a family affair. | Haematologica | 2020 |
| 32685011 | TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. | Theranostics | 2020 |
| 32144272 | Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. | Nat Commun | 2020 |
| 32298201 | Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. | J Clin Oncol | 2020 |
| 30332496 | Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. | Cancer | 2019 |
| 31698452 | Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. | Blood Adv | 2019 |
| 31767829 | Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. | Blood Cancer J | 2019 |
| 31582370 | Myeloma's sound of silencing. | Blood | 2019 |
| 31405035 | Cancer Metabolism and the Evasion of Apoptotic Cell Death. | Cancers (Basel) | 2019 |
| 31231360 | Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. | Front Immunol | 2019 |
| 31043428 | Stromal Support of Metabolic Function through Mitochondrial Transfer in Multiple Myeloma. | Cancer Res | 2019 |
| 31013254 | Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. | JCI Insight | 2019 |
| 31090928 | Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. | Cancer | 2019 |
| 31023594 | Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. | Clin Lymphoma Myeloma Leuk | 2019 |
| 30679802 | Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. | Leukemia | 2019 |
| 30480777 | Safety and survival outcomes for bloodless transplantation in patients with myeloma. | Cancer | 2019 |
| 30701088 | The prodomain of caspase-3 regulates its own removal and caspase activation. | Cell Death Discov | 2019 |
| 28924240 | 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. | Leukemia | 2018 |
| 30190351 | A miRaculous new therapy in myeloma? | Blood | 2018 |
| 30033091 | MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. | Cancer Cell | 2018 |
| 30004825 | Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. | J Oncol Pract | 2018 |
| 29775995 | Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming. | FEBS J | 2018 |
| 27878989 | Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. | FEBS Lett | 2017 |
| 28089569 | Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. | Cell Metab | 2017 |